Powered By
Overview
Trintellix is a prescription drug approved by the Food and Drug Administration (FDA) to treat major depressive disorder. Trintellix is also referred to by its drug name, Vortioxetine. Trintellix was previously… read more
Overview
Provigil is a prescription medication approved by the Food and Drug Administration (FDA) for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder.… read more
Overview
Spravato is a prescription drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with treatment-resistant depression (TRD), either alone or in combination with an oral…
Overview
Cobenfy is a combination medication of xanomeline, a muscarinic agonist, and trospium chloride, a muscarinic antagonist, approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia…
Overview
Erzofri, approved by the U.S. Food and Drug Administration (FDA), is an atypical (second-generation) antipsychotic drug used for treating schizophrenia in adults. People who are new to Erzofri or similar drugs…
Overview
Abilify is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia, the acute treatment of manic and mixed episodes associated with bipolar 1 disorder, and as an adjunctive…
Overview
Abilify Maintena is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia and the maintenance monotherapy (single-drug treatment) of bipolar 1 disorder in adults. This…
Overview
Abilify Asimtufii is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults and as a maintenance monotherapy (single-drug treatment) for bipolar 1 disorder in adults…
Overview
Brixadi is approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe opioid use disorder in individuals who have started treatment with a transmucosal buprenorphine product…
Overview
Saphris is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults and for the treatment of bipolar 1 disorder in both adults and children aged 10 to 17. For bipolar 1…
Join